Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer-Reference-Cited by-同舟云学术

Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer

Published:2019-01-24 Issue:4 Volume:41 Page:908-914
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Mennini FS¹²,Marcellusi A¹²,Fabiano G¹²,Platini F³,Bossi P³^ORCID

Affiliation:

1. Economic Evaluation and HTA (CEIS‐EEHTA) ‐ Faculty of EconomicsUniversity of Rome “Tor Vergata” Rome Italy

2. Department of Accounting, Finance and InformaticsInstitute for Leadership and Management in Health ‐ Kingston University London London United Kingdom

3. Head and Neck Medical Oncology DepartmentFondazione IRCCS Istituto Nazionale Tumori Milano Milan Italy

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.25481

Reference25 articles.

1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

2. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

3. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma

4. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study

5. Administration of Cetuximab Every 2 Weeks in the Treatment of Metastatic Colorectal Cancer: An Effective, More Convenient Alternative to Weekly Administration?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of an alternative reconstructed individual patient data-based approach for budget impact analysis of anticancer drugs;Cost Effectiveness and Resource Allocation;2023-06-11

2. Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer;International Journal of Clinical Oncology;2022-08-09

3. Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study;Frontiers in Public Health;2021-11-05